Oseltamivir-induced neuropsychiatric symptoms

Arshad Basha Shaik, Mukhyaprana Prabhu, Smita Shenoy, Sereen Rose Thomson

Research output: Contribution to journalArticle

Abstract

Oseltamivir is a viral neuraminidase enzyme inhibitor commonly prescribed for prevention and management of influenza. Common adverse effects of oseltamivir are gastrointestinal side effects such as nausea, vomiting, diarrhea, and pain abdomen; others are headache, insomnia, cough, skin rashes, and sadness. In 2006, US Food and Drug Administration added a warning to the label of oseltamivir drawing attention to the risk of developing neuropsychiatric adverse events (NPAE). However, the incidence of NPAE with oseltamivir has been underreported in India. Hence, in our report, we present the occurrence of neuropsychiatric symptoms such as aggressive behavior, restlessness, hallucinations, paranoid ideas, and insomnia following administration of oseltamivir in a young adult female patient.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalJournal of Pharmacology and Pharmacotherapeutics
Volume9
Issue number1
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Oseltamivir
Sleep Initiation and Maintenance Disorders
Primary Headache Disorders
Psychomotor Agitation
Hallucinations
Neuraminidase
Enzyme Inhibitors
United States Food and Drug Administration
Exanthema
Abdomen
Nausea
Human Influenza
Vomiting
India
Young Adult
Diarrhea
Pain
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{f17bb821b6454111b6e92eba597e6e3e,
title = "Oseltamivir-induced neuropsychiatric symptoms",
abstract = "Oseltamivir is a viral neuraminidase enzyme inhibitor commonly prescribed for prevention and management of influenza. Common adverse effects of oseltamivir are gastrointestinal side effects such as nausea, vomiting, diarrhea, and pain abdomen; others are headache, insomnia, cough, skin rashes, and sadness. In 2006, US Food and Drug Administration added a warning to the label of oseltamivir drawing attention to the risk of developing neuropsychiatric adverse events (NPAE). However, the incidence of NPAE with oseltamivir has been underreported in India. Hence, in our report, we present the occurrence of neuropsychiatric symptoms such as aggressive behavior, restlessness, hallucinations, paranoid ideas, and insomnia following administration of oseltamivir in a young adult female patient.",
author = "Shaik, {Arshad Basha} and Mukhyaprana Prabhu and Smita Shenoy and Thomson, {Sereen Rose}",
year = "2018",
month = "1",
day = "1",
doi = "10.4103/jpp.JPP_121_17",
language = "English",
volume = "9",
pages = "43--45",
journal = "Journal of Pharmacology and Pharmacotherapeutics",
issn = "0976-500X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

Oseltamivir-induced neuropsychiatric symptoms. / Shaik, Arshad Basha; Prabhu, Mukhyaprana; Shenoy, Smita; Thomson, Sereen Rose.

In: Journal of Pharmacology and Pharmacotherapeutics, Vol. 9, No. 1, 01.01.2018, p. 43-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oseltamivir-induced neuropsychiatric symptoms

AU - Shaik, Arshad Basha

AU - Prabhu, Mukhyaprana

AU - Shenoy, Smita

AU - Thomson, Sereen Rose

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oseltamivir is a viral neuraminidase enzyme inhibitor commonly prescribed for prevention and management of influenza. Common adverse effects of oseltamivir are gastrointestinal side effects such as nausea, vomiting, diarrhea, and pain abdomen; others are headache, insomnia, cough, skin rashes, and sadness. In 2006, US Food and Drug Administration added a warning to the label of oseltamivir drawing attention to the risk of developing neuropsychiatric adverse events (NPAE). However, the incidence of NPAE with oseltamivir has been underreported in India. Hence, in our report, we present the occurrence of neuropsychiatric symptoms such as aggressive behavior, restlessness, hallucinations, paranoid ideas, and insomnia following administration of oseltamivir in a young adult female patient.

AB - Oseltamivir is a viral neuraminidase enzyme inhibitor commonly prescribed for prevention and management of influenza. Common adverse effects of oseltamivir are gastrointestinal side effects such as nausea, vomiting, diarrhea, and pain abdomen; others are headache, insomnia, cough, skin rashes, and sadness. In 2006, US Food and Drug Administration added a warning to the label of oseltamivir drawing attention to the risk of developing neuropsychiatric adverse events (NPAE). However, the incidence of NPAE with oseltamivir has been underreported in India. Hence, in our report, we present the occurrence of neuropsychiatric symptoms such as aggressive behavior, restlessness, hallucinations, paranoid ideas, and insomnia following administration of oseltamivir in a young adult female patient.

UR - http://www.scopus.com/inward/record.url?scp=85050116932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050116932&partnerID=8YFLogxK

U2 - 10.4103/jpp.JPP_121_17

DO - 10.4103/jpp.JPP_121_17

M3 - Article

AN - SCOPUS:85050116932

VL - 9

SP - 43

EP - 45

JO - Journal of Pharmacology and Pharmacotherapeutics

JF - Journal of Pharmacology and Pharmacotherapeutics

SN - 0976-500X

IS - 1

ER -